首页> 美国卫生研究院文献>The CRISPR Journal >Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa
【2h】

Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa

机译:视紫红质相关性主要视网膜色素变性的单碱基P23H突变的等位基因特异性CRISPR-Cas9基因组编辑。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Treatment strategies for dominantly inherited disorders typically involve silencing or ablating the pathogenic allele. CRISPR-Cas nucleases have shown promise in allele-specific knockout approaches when the dominant allele creates unique protospacer adjacent motifs that can lead to allele-restricted targeting. Here, we present a spacer-mediated allele-specific knockout approach that utilizes both SpCas9 variants and truncated single-guide RNAs to achieve efficient discrimination of a single-nucleotide mutation in rhodopsin (Rho)-P23H mice, a model of dominant retinitis pigmentosa. We found that approximately 45% of the mutant P23H allele was edited at the DNA level and that the relative RNA expression of wild-type Rho was about 2.8 times more than that of mutant Rho in treated retinas. Furthermore, the progression of photoreceptor cell degeneration in outer nuclear layer was significantly delayed in treated regions of the Rho-P23H retinas at 5 weeks of age. Our proof-of-concept study therefore outlines a general strategy that could potentially be expanded to examine the therapeutic benefit of allele-specific gene editing approach to treat human P23H patients. Our study also extends allele-specific editing strategies beyond discrimination within the protospacer adjacent motif sites, with potentially broad applicability to other dominant diseases.
机译:显性遗传疾病的治疗策略通常涉及沉默或消融病原体等位基因。当优势等位基因产生独特的原间隔子相邻基序并可能导致等位基因限制性靶向时,CRISPR-Cas核酸酶已在等位基因特异性敲除方法中显示出前景。在这里,我们介绍了一种间隔子介导的等位基因特异性敲除方法,该方法利用SpCas9变体和截短的单向导RNA来有效识别视紫红质(Rho)-P23H小鼠(一种占主导地位的视网膜色素变性的模型)中的单核苷酸突变。我们发现,在DNA水平上大约编辑了45%的突变体P23H等位基因,在治疗的视网膜中,野生型Rho的相对RNA表达约为突变体Rho的2.8倍。此外,Rho-P23H视网膜的治疗区域在5周龄时,外核层中感光细胞变性的进程被显着延迟。因此,我们的概念验证研究概述了一种总体策略,该策略可能会扩展为检查等位基因特异性基因编辑方法对人类P23H患者的治疗效果。我们的研究还将等位基因特异的编辑策略扩展到了原间隔子相邻基序位点的识别范围之外,并可能广泛应用于其他优势疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号